An announcement from Xencor ( (XNCR) ) is now available.
On March 13, 2025, Xencor announced the appointment of Todd Simpson to its Board of Directors and Audit Committee. With over 40 years of experience in financial leadership roles, including as CFO at Seagen Inc., Simpson’s expertise is expected to enhance Xencor’s strategic and operational capabilities, potentially strengthening its position in the biopharmaceutical industry.
More about Xencor
Xencor is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for treating cancer and autoimmune diseases. The company utilizes its XmAb® technology to create new therapeutic mechanisms, with over 20 candidates in clinical development and multiple marketed medicines through partnerships.
YTD Price Performance: -44.81%
Average Trading Volume: 624,053
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $947.7M
For detailed information about XNCR stock, go to TipRanks’ Stock Analysis page.